Yahoo Suche Web Suche

Anmelden

Suchergebnisse

  1. Suchergebnisse:

  1. de.wikipedia.org › wiki › John_FJohn F. Seymour – Wikipedia

    John F. Seymour (* 3. Dezember 1937 in Chicago, Illinois) ist ein US-amerikanischer Immobilieninvestor und Politiker ( Republikanische Partei ), der den Bundesstaat Kalifornien im US-Senat vertrat.

  2. scholar.google.com › citations‪John F Seymour‬ - ‪Google Scholar‬

    John F Seymour. Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne. Verified email at petermac.org - Homepage. Hematologic malignancies....

  3. Bilder

    • John F Seymour - Alchetron, The Free Social Encyclopedia
    • Photos de John Seymour - Babelio.com
    • [Police Chief John F. Seymour] — Calisphere
    • John Seymour (author) - Alchetron, The Free Social Encyclopedia
    • The Hessian Sack: The Age of Healing by John Seymour
    • John Seymour (1474-1536) – kleio.org

    Alle anzeigen

  4. www.nejm.org › doi › fullVenetoclax–Rituximab in Relapsed or Refractory Chronic...

    21. März 2018 · Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

    • John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline...
    • 2018

  5. ashpublications.org › blood › articleDegraders upgraded: the rise of PROTACs in hematological...

    28. März 2024 · Casan and Seymour provide a state-of-the-art review of proteolysis-targeting chimeras (PROTACs), the leading class of targeted protein degradation agents.

  6. www.researchgate.net › John-F-Seymour-39836103John F Seymour's research works | Peter MacCallum Cancer Centre...

    John F. Seymour. Background: Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma (NHL). Several treatment options are approved by the US Food and Drug...

  7. www.onclive.com › authors › john-f-seymour-mbbs-phdJohn F. Seymour, MBBS, PhD - OncLive

    John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer...

  8. ashpublications.org › blood › articleAssessing the Burden of Adverse Events in a Head-to-Head Trial of...

    15. Nov. 2022 · Abstract. Background: In a previously reported phase 3 head-to-head trial of the Bruton tyrosine kinase (BTK) inhibitors acalabrutinib (Acala) and ibrutinib (Ibr) (NCT02477696), Acala demonstrated noninferiority to Ibr and an improved safety profile with statistically fewer atrial fibrillation/flutter (afib/flutter) events (9% vs 16% ...